Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema

Clinical and Experimental Ophthalmology

Volumn 39, Issue 7, 2011, Pages 673-681

  Sheth, Saumil ^a   Rush, Ryan ^b   Natarajan, Sundaram ^c   Gillies, Mark ^a  

^a SYDNEY EYE HOSPITAL   (Australia)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c ADITYA JYOT EYE HOSPITAL PVT LTD   (India)

Author keywords

Diabetic macular oedema; Intravitreal dexamethasone and bevacizumab; Intravitreal triamcinolone acetonide; Spectral domain optical coherence tomography

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; TIMOLOL MALEATE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; PROSPECTIVE STUDY; PSEUDOPHAKIA; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; SINGLE DRUG DOSE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 80053563597     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2011.02504.x     Document Type: Article

References (22)

1. Early Treatment Diabetic Retinopathy Study Report Number 1. Photocoagulation for diabetic macular edema. Arch Ophthalmol 1985; 103: 1796-805.
2. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-9.
3. Kim BY, Smith SD, Kaiser PK. Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol 2006; 142: 405-12.
4. Kim NR, Kim YJ, Chin HS, Moon YS. Optical coherence tomographic patterns in diabetic macular oedema: prediction of visual outcome after focal laser photocoagulation. Br J Ophthalmol 2009; 93: 901-5.
5. Kim JE, Pollack JS, Miller DG, Mittra RA, Spaide RF; Isis Study Group. ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina 2008; 28: 735-40.
6. Gillies MC, Simpson JM, Gaston C etal. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009; 116: 2182-7.
7. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132: 425-7.
8. Audren F, Lecleire-Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4mg vs. 2mg. Am J Ophthalmol 2006; 142: 794-99.
9. Hirooka K, Shiraga F, Tanaka S, Baba T, Mandai H. Risk factors for elevated intraocular pressure after trans-tenon retrobulbar injections of triamcinolone. Jpn J Ophthalmol 2006; 50: 235-8.
10. Michaelides M, Kaines A, Hamilton RD etal. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117: 1078-86.
11. Soheilian M, Ramezani A, Bijanzadeh B etal. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007; 27: 1187-95.
12. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008; 92: 76-80.
13. Chan CK, Mohamed S, Lee VY, Lai TY, Shanmugam MP, Lam DS. Intravitreal dexamethasone for diabetic macular edema: a pilot study. Ophthalmic Surg Lasers Imaging 2010; 41: 26-30.
14. Chylack LT, Wolfe JK, Singer DM etal. The lens opacities classification system III. Arch Ophthalmol 1993; 111: 831-6.
15. Browning DJ, Glassman AR, Aiello LP etal. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology 2008; 115: 1366-71.
16. Chan A, Duker JS. A standardized method for reporting changes in macular thickening using optical coherence tomography. Arch Ophthalmol 2005; 123: 939-43.
17. Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114: 525-36.
18. Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005; 139: 802-6.
19. Massin P, Audren F, Haouchine B etal. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218-24.
20. Sutter FKP, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Ophthalmology 2004; 111: 2044-9.
21. Haritoglou C, Kook D, Neubauer A etal. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
22. Soheilian M, Ramezani A, Obudi A etal. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116: 1142-50.